Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients

NCT03943589 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT03943589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03943589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients
Lead sponsor
Hansa Biopharma AB
Phase
Phase 2
Overall status
Completed
Start date
November 12, 2019
Completion date
February 27, 2024
Enrollment
30 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

guillain-barré syndrome (gbs)